Pfizer Inc. (PFE) on Tuesday reported positive topline results from the Phase 2 FOURLIGHT-1 study evaluating atirmociclib in combination with fulvestrant in people with hormone receptor (HR)-positive, human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer.
The study met its primary endpoint, showing a statistically significant and clinically meaningful improvement in progression-free survival.
FOURLIGHT-1 evaluated atirmociclib plus fulvestrant compared with fulvestrant alone or everolimus in combination with exemestane in adults receiving second-line treatment for advanced or metastatic breast cancer.
The progression-free survival benefit was consistent across all prespecified subgroups, including patients with differing performance status, menopausal status, presence of visceral disease, and prior exposure to CDK4/6 inhibitors.
"The strength of these data reinforces our confidence that atirmociclib may meaningfully differentiate from the CDK4/6 inhibitor class, the standard-of-care backbone in HR-positive breast cancer, with the potential for improved efficacy and tolerability," said Jeff Legos, Chief Oncology Officer, Pfizer.
On Monday, Pfizer shares closed at $26.61, up 0.11%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.